The Simple AI-Agent Playbook for Finding Opportunities in Telehealth Skincare

Transcript

A market worth $12.82 billion in 2022, projected to grow at 14.2% annually through 2030, and most people still think of it as "just seeing a doctor on your phone." That framing undersells what actually happened. The global teledermatology boom, tracked by Grand View Research, was not driven by convenience alone. It was driven by a specific insight: prescription skincare is a recurring, high-margin product that maps perfectly onto a subscription model. Once founders saw that, the race was on. Think of it like a vending machine that also writes you a prescription. Curology, founded in 2014, built exactly that. A patient uploads a photo, a licensed provider reviews it, and a custom formula ships to your door every month. Forbes reported that by 2021, Curology had crossed one million active patients. That is not a niche audience. That is proof of a scalable, repeatable demand signal. Hims and Hers took a similar playbook and went even bigger. TechCrunch confirmed the company went public via a SPAC merger in January 2021 at an initial valuation of approximately $1.6 billion. The growth lever for both companies was the same: remove the waiting room, own the subscription, and control the formula. Apostrophe followed a comparable path, targeting a slightly more clinical, acne-focused audience. Musely, operating in the US, leaned into physician-formulated compounded treatments, differentiating on potency and customization. Each company proved one thing clearly. Patients will pay monthly for personalized prescription skincare if the friction is low enough. Now, Smriti, here is where the newer wave gets interesting. Skin and Me launched in the UK in 2020 and applied this exact subscription-prescription model to the European market. Tech.eu reported the company raised over ten million pounds in Series B funding. What Skin and Me understood was that the first-wave companies had solved acquisition but not long-term personalization. The key idea is that a patient's skin changes. A static formula assigned at signup becomes less effective over time. The differentiation play for newer entrants is dynamic treatment adjustment, using ongoing check-ins and data to evolve the prescription. That is the gap where AI-native tools now have enormous leverage. An agent that monitors patient-reported outcomes and flags when a formula needs updating is not science fiction. It is a workflow problem. And workflow problems are exactly what Claude agents solve. That means you can build a practical version of this research and triage system yourself, and it does not require engineering skills. Here is the step-by-step approach. First, open Claude and assign it a clear role in your prompt. For example, write something like: "You are my investment research assistant. Your job is to read the following email summaries and flag anything related to telehealth, skincare startups, or AI health tools as High, Medium, or Low priority." Second, paste in your email digest or newsletter content directly. Third, create a second prompt for source monitoring. Give Claude a list of ten to twenty sources you trust, such as TechCrunch, Stat News, Rock Health, or CB Insights, and instruct it to extract company names, funding rounds, and strategic moves from any content you paste from those outlets. Fourth, build a daily briefing prompt that asks Claude to synthesize both outputs into five bullet points: what needs action today, what is worth watching, and what can be ignored. This three-agent structure, an email triage agent, an investment scout agent, and a daily briefing agent, gives you a command center that runs on your schedule. The takeaway here is that you are not replacing judgment. You are eliminating the noise that buries it. The real opportunity in AI-native skincare, Smriti, is not just building another teledermatology app. It is the workflow advantage. Curology, Apostrophe, and Hims and Hers proved that consumers want remote prescription skincare and will subscribe to it. What they could not do cheaply was personalize at scale and monitor patients continuously without adding headcount. An AI agent changes that equation entirely. Remember this: the companies that win the next decade in this space will not just have better formulas. They will have better loops, smarter intake, automated follow-up, and agents that surface the right investment signal before the rest of the market sees it. That is the edge you are building right now.